RESUMO
Chorioamnionitis (CA) is a risk factor for preterm birth and is associated with neurodevelopmental delay and cognitive disorders. Prenatal inflammation-induced brain injury may resolve during the immediate postnatal period when rapid brain remodeling occurs. Cerebrospinal fluid (CSF) collected at birth may be a critical source of predictive biomarkers. Using pigs as a model of preterm infants exposed to CA, we hypothesized that prenatal lipopolysaccharide (LPS) exposure induces proteome changes in the CSF and brain at birth and postnatally. Fetal piglets (103 days gestation of full-term at 117 days) were administered intra-amniotic (IA) lipopolysaccharide (LPS) 3 days before preterm delivery by caesarian section. CSF and brain tissue were collected on postnatal Days 1 and 5 (P1 and P5). CSF and hippocampal proteins were profiled by LC-MS-based quantitative proteomics. Neuroinflammatory responses in the cerebral cortex, periventricular white matter and hippocampus were evaluated by immunohistochemistry, and gene expression was evaluated by qPCR. Pigs exposed to LPS in utero showed changes in CSF protein levels at birth but not at P5. Complement protein C3, hemopexin, vasoactive intestinal peptide, carboxypeptidase N subunit 2, ITIH1, and plasminogen expression were upregulated in the CSF, while proteins associated with axon growth and synaptic functions (FGFR1, BASP1, HSPD1, UBER2N, and RCN2), adhesion (talin1), and neuronal survival (Atox1) were downregulated. Microglia, but not astrocytes, were activated by LPS at P5 in the hippocampus but not in other brain regions. At this time, marginal increases in complement protein C3, LBP, HIF1a, Basp1, Minpp1, and FGFR1 transcription indicated hippocampal proinflammatory responses. In conclusion, few days exposure to endotoxin prenatally induce proteome changes in the CSF and brain at birth, but most changes resolve a few days later. The developing hippocampus has high neuronal plasticity in response to perinatal inflammation. Changes in CSF protein expression at birth may predict later structural brain damage in preterm infants exposed to variable types and durations of CA-related inflammation in utero.
Assuntos
Lesões Encefálicas , Corioamnionite , Nascimento Prematuro , Animais , Encéfalo , Lesões Encefálicas/complicações , Proteínas de Ligação ao Cálcio , Corioamnionite/induzido quimicamente , Proteínas do Sistema Complemento/efeitos adversos , Proteínas de Transporte de Cobre , Endotoxinas/toxicidade , Feminino , Humanos , Recém-Nascido , Recém-Nascido Prematuro , Inflamação , Lipopolissacarídeos/farmacologia , Chaperonas Moleculares , Gravidez , Proteoma , Proteômica , SuínosAssuntos
Síndrome Hemolítico-Urêmica Atípica/patologia , COVID-19/complicações , Proteínas do Sistema Complemento/efeitos adversos , SARS-CoV-2/isolamento & purificação , Adulto , Idoso , Síndrome Hemolítico-Urêmica Atípica/etiologia , COVID-19/transmissão , COVID-19/virologia , Feminino , Humanos , MasculinoRESUMO
Advances in animal transgenesis may allow using xenogeneic chondrocytes in tissue-engineering applications for clinical cartilage repair. Porcine cartilage is rejected by humoral and cellular mechanisms that could be overcome by identifying key molecules triggering rejection and developing effective genetic-engineering strategies. Accordingly, high expression of α1,2-fucosyltransferase (HT) in xenogeneic cartilage protects from galactose α1,3-galactose (Gal)-mediated antibody responses. Now, we studied whether expression of a complement inhibitor provides further protection. First, porcine articular chondrocytes (PAC) were isolated from non-transgenic, single and double transgenic pigs expressing HT and moderate levels of human CD59 (hCD59) and their response to human serum was assessed. High recombinant expression of human complement regulatory molecules hCD59 and hDAF was also attained by retroviral transduction of PAC for further analyses. Complement activation on PAC after exposure to 20 % human serum for 24 hours mainly triggered the release of pro-inflammatory cytokines IL-6 and IL-8. Transgenic expression of HT and hCD59 did not suffice to fully counteract this effect. Nevertheless, the combination of blocking anti-Gal antibodies (or C5a) and high hCD59 levels conferred very high protection. On the contrary, high hDAF expression attained the most dramatic reduction in IL-6/IL-8 secretion by a single strategy, but the additional inhibition of anti-Gal antibodies or C5a did not provide further improvement. Notably, we demonstrate that both hCD59 and hDAF inhibit anaphylatoxin release in this setting. In conclusion, our study identifies genetic-engineering approaches to prevent humoral rejection of xenogeneic chondrocytes for use in cartilage repair.
Assuntos
Anticorpos/imunologia , Cartilagem/citologia , Condrócitos/citologia , Proteínas do Sistema Complemento/efeitos adversos , Animais , Animais Geneticamente Modificados , Modelos Animais de Doenças , Engenharia Genética , Suínos , Transplante Heterólogo/métodosRESUMO
Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by complement-mediated intravascular hemolysis because of the lack from erythrocyte surface of the complement regulators CD55 and CD59, with subsequent uncontrolled continuous spontaneous activation of the complement alternative pathway (CAP), and at times of the complement classic pathway. Here we investigate in an in vitro model the effect on PNH erythrocytes of a novel therapeutic strategy for membrane-targeted delivery of a CAP inhibitor. TT30 is a 65 kDa recombinant human fusion protein consisting of the iC3b/C3d-binding region of complement receptor 2 (CR2) and the inhibitory domain of the CAP regulator factor H (fH). TT30 completely inhibits in a dose-dependent manner hemolysis of PNH erythrocytes in a modified extended acidified serum assay, and also prevents C3 fragment deposition on surviving PNH erythrocytes. The efficacy of TT30 derives from its direct binding to PNH erythrocytes; if binding to the erythrocytes is disrupted, only partial inhibition of hemolysis is mediated by TT30 in solution, which is similar to that produced by the fH moiety of TT30 alone, or by intact human fH. TT30 is a membrane-targeted selective CAP inhibitor that may prevent both intravascular and C3-mediated extravascular hemolysis of PNH erythrocytes and warrants consideration for the treatment of PNH patients.
Assuntos
Fator H do Complemento/química , Eritrócitos/efeitos dos fármacos , Hemoglobinúria Paroxística/sangue , Hemólise/efeitos dos fármacos , Proteínas de Fusão Oncogênica/farmacologia , Receptores de Complemento 3d/química , Proteínas Recombinantes de Fusão/farmacologia , Estudos de Casos e Controles , Células Cultivadas , Complemento C3/efeitos adversos , Complemento C3/antagonistas & inibidores , Complemento C3/farmacologia , Fator H do Complemento/metabolismo , Fator H do Complemento/farmacologia , Proteínas do Sistema Complemento/efeitos adversos , Proteínas do Sistema Complemento/fisiologia , Citoproteção/efeitos dos fármacos , Avaliação Pré-Clínica de Medicamentos , Eritrócitos/fisiologia , Hemoglobinúria Paroxística/patologia , Humanos , Proteínas de Fusão Oncogênica/metabolismo , Ligação Proteica , Receptores de Complemento 3d/metabolismo , Receptores de Complemento 3d/fisiologia , Proteínas Recombinantes de Fusão/metabolismoRESUMO
Neuromyelitis optica is an inflammatory demyelinating disease of the central nervous system associated with autoantibodies against the glial water channel protein aquaporin-4. It has recently been reported that immunoglobulin from neuromyelitis optica patients injected peripherally does not cause lesions in naive rats, but only when pre-existing central nervous system inflammation is present. Here, we investigated whether immunoglobulin G from aquaporin-4-autoantibody-positive neuromyelitis optica patients has the potential to damage the central nervous system either alone or in the presence of human complement. Immunoglobulin G from neuromyelitis optica patients did not activate mouse complement and was not pathogenic when injected into mouse brain. However, co-injection of immunoglobulin G from neuromyelitis optica patients with human complement produced neuromyelitis optica-like lesions in mice. Within 12 h of co-injecting immunoglobulin G from neuromyelitis optica patients and human complement, there was a striking loss of aquaporin-4 expression, glial cell oedema, myelin breakdown and axonal injury, but little intra-parenchymal inflammation. At 7 days, there was extensive inflammatory cell infiltration, perivascular deposition of activated complement components, extensive demyelination, loss of aquaporin-4 expression, loss of reactive astrocytes and neuronal cell death. In behavioural studies, mice injected with immunoglobulin G from neuromyelitis optica patients and human complement into the right hemisphere preferentially turned to the right at 7 days. No brain inflammation, demyelination or right-turning behaviour was seen in wild-type mice that received immunoglobulin G from non-neuromyelitis optica patients with human complement, or in aquaporin-4-null mice that received immunoglobulin G from neuromyelitis optica patients with human complement. We conclude that co-injection of immunoglobulin G from neuromyelitis optica patients with human complement reproduces the key histological features of neuromyelitis optica and that aquaporin-4 is necessary and sufficient for immunoglobulin G from neuromyelitis optica patients to exert its effect. In our mouse model, immunoglobulin G from neuromyelitis optica patients does not require pre-existing central nervous system inflammation to produce lesions.
Assuntos
Proteínas do Sistema Complemento/efeitos adversos , Modelos Animais de Doenças , Imunoglobulina G/efeitos adversos , Neuromielite Óptica/imunologia , Neuromielite Óptica/patologia , Animais , Aquaporina 4/imunologia , Autoanticorpos/biossíntese , Células CHO , Proteínas do Sistema Complemento/administração & dosagem , Cricetinae , Cricetulus , Humanos , Imunoglobulina G/administração & dosagem , Injeções Intraventriculares , Camundongos , Camundongos KnockoutRESUMO
PURPOSE OF REVIEW: We have selectively reviewed some of the latest papers on the mechanistic role of C-reactive protein in atherosclerotic cardiovascular disease. RECENT DEVELOPMENTS: C-reactive protein is known to activate the classic pathway of the complement system. One paper examined the role of C-reactive protein in complement activation by enzymatically remodeled LDL proteins. Enzymatically remodeled LDL was found to induce complement activation with or without C-reactive protein, but in the presence of C-reactive protein the activation of complement halted before its terminal sequence. Complement activation by C-reactive protein in atherogenesis remains controversial. Different laboratories have reported the multi-organ origin of C-reactive protein. The atherosclerotic lesion itself is another place where C-reactive protein could be produced. Numerous studies have continued to dissect the potential diverse proatherogenic actions of C-reactive protein on cultured vascular cells. Caution must be exercised in inadequately controlled studies that have unwittingly used commercial C-reactive protein preparations contaminated by other bioactive components. In contrast to in-vitro experiments, in-vivo studies that support a proatherogenic role of C-reactive protein are less likely to be subject to misinterpretation. SUMMARY: Evidence suggests that C-reactive protein is a proatherogenic molecule that plays an active role. The amount of C-reactive protein in lesions is determined by its plasma levels and its local production. The biological effect of C-reactive protein on atherosclerosis development seems to encompass a complex network of interactions with other players in immunity and inflammation, such as the complement system, as well as a direct effect of C-reactive protein on the cells involved in lesion growth and development.
Assuntos
Aterosclerose/etiologia , Aterosclerose/metabolismo , Proteína C-Reativa/efeitos adversos , Proteína C-Reativa/fisiologia , Proteínas do Sistema Complemento/fisiologia , Animais , Aterosclerose/imunologia , Ativação do Complemento , Proteínas do Sistema Complemento/efeitos adversos , HumanosRESUMO
By using an in vitro model of antibody-mediated demyelination, we investigated the relationship between tumor necrosis factor-alpha (TNF-alpha) and heat shock protein (HSP) induction with respect to oligodendrocyte survival. Differentiated aggregate cultures of rat telencephalon were subjected to demyelination by exposure to antibodies against myelin oligodendrocyte glycoprotein (MOG) and complement. Cultures were analyzed 48 hr after exposure. Myelin basic protein (MBP) expression was greatly decreased, but no evidence was found for either necrosis or apoptosis. TNF-alpha was significantly up-regulated. It was localized predominantly in neurons and to a lesser extent in astrocytes and oligodendrocytes, and it was not detectable in microglial cells. Among the different HSPs examined, HSP32 and alphaB-crystallin were up-regulated; they may confer protection from oxidative stress and from apoptotic death, respectively. These results suggest that TNF-alpha, often regarded as a promoter of oligodendroglial death, could alternatively mediate a protective pathway through alphaB-crystallin up-regulation.
Assuntos
Anticorpos/efeitos adversos , Cristalinas/metabolismo , Doenças Desmielinizantes/metabolismo , Oligodendroglia/efeitos dos fármacos , Telencéfalo/citologia , Fator de Necrose Tumoral alfa/metabolismo , 2',3'-Nucleotídeo Cíclico Fosfodiesterases/metabolismo , Animais , Apoptose/fisiologia , Western Blotting/métodos , Células Cultivadas , Proteínas do Sistema Complemento/efeitos adversos , Doenças Desmielinizantes/induzido quimicamente , Modelos Animais de Doenças , Interações Medicamentosas , Embrião de Mamíferos , Proteína Glial Fibrilar Ácida/metabolismo , Heme Oxigenase (Desciclizante)/metabolismo , Heme Oxigenase-1 , Imuno-Histoquímica/métodos , Hibridização In Situ/métodos , Proteína Básica da Mielina/genética , Proteína Básica da Mielina/metabolismo , Proteínas da Mielina , Glicoproteína Associada a Mielina/imunologia , Glicoproteína Mielina-Oligodendrócito , Necrose/metabolismo , Neurônios/efeitos dos fármacos , Neurônios/metabolismo , Ratos , Regulação para CimaRESUMO
Because activation of the complement system plays a major role in the pathogenesis of acute lung injury, the availability of new specific complement inhibitors represents a promising therapeutic approach. In the present study we investigated pulmonary edema formation and pulmonary artery pressure (PAP) in acute complement-induced lung injury for possible therapeutic impact of the complement regulators C1 inhibitor and soluble complement receptor 1. Eighteen isolated and ventilated rabbit lungs were perfused with pooled normal human serum (NHS, final concentration 35%) in Krebs-Henseleit buffer in a recirculating system. Lung weight gain and PAP were continuously recorded. Complement activation was blocked by the addition of C1 inhibitor (1.0 U/mL, n = 6) or sCR 1 (2.0 microg/mL, n = 6). Lungs that received NHS without inhibitors served as controls (n = 6). This study was performed according to the Helsinki Declaration and approved by the local government. Application of NHS resulted in an increase of PAP within 20 min from 8+/-2 to 42+/-6 mmHg, which was significantly (P < 0.05) decreased by C1-Inh (25+/-5 mmHg) and sCRI (20 +/-3 mmHg). Moreover, pulmonary edema formation after NHS, as assessed by overall weight gain, was reduced by both C1-Inh and sCR1, compared with controls. These findings were paralleled with significantly decreased thromboxane release rates and reduced tissue deposition of C3c and C5b-9. C1 inhibitor and sCR1 attenuate the complement-induced pulmonary capillary leakage and PAP increase, indicating the protective effect of complement inhibition in isolated perfused rabbit lungs.
Assuntos
Pressão Sanguínea/fisiologia , Proteínas Inativadoras do Complemento 1/farmacologia , Pulmão/efeitos dos fármacos , Artéria Pulmonar/fisiologia , Receptores de Complemento/uso terapêutico , Animais , Pressão Sanguínea/efeitos dos fármacos , Ativação do Complemento , Convertases de Complemento C3-C5/análise , Complexo de Ataque à Membrana do Sistema Complemento/análise , Proteínas do Sistema Complemento/efeitos adversos , Feminino , Humanos , Técnicas In Vitro , Pulmão/patologia , Perfusão , Artéria Pulmonar/efeitos dos fármacos , Edema Pulmonar/etiologia , Edema Pulmonar/prevenção & controle , Coelhos , Tromboxano B2/metabolismoRESUMO
The xenotransplantation research is driven by the shortage of allografts for transplantation of patients with end-stage organ failure and by lack of success in developing suitable artificial organs. Pigs are now generally accepted to be the donor species of choice, although a possible risk for transmission of xenozoonoses, particularly pig endogenous retroviruses, should be born in mind. A vascular xenograft from pig to human is usually rejected hyperacutely due to naturally occurring antibodies and complement. This hyperacute rejection can be prevented by manipulating with either of these systems. In this review we briefly describe the hyperacute rejection and how it can be prevented by complement modulation. Pigs made transgenic for human complement regulatory proteins seem very promising for future clinical experiments. Control of fluid-phase complement activation should be obtained as well. The latter is discussed based on our own recent studies in this field.
Assuntos
Proteínas do Sistema Complemento/efeitos adversos , Proteínas do Sistema Complemento/fisiologia , Transplante Heterólogo/métodos , Animais , Humanos , Transplante Heterólogo/efeitos adversosRESUMO
High-dose intravenous immune globulin (IVIG) exerts a beneficial effect in a variety of immune disorders. One possible underlying mechanism of this effect could be interference with the complement system. This conclusion was based on the results obtained in animal models of complement-mediated pathology, in vitro complement assays and studies on related human diseases. Clearance of IgM-sensitized erythrocytes was specifically suppressed by IVIG treatment. The same therapy prevented pulmonary endothelial cell lesions, the hallmark of Forssman shock, in 75% of animals. All control animals, either untreated or injected with control reagents, died within minutes following induction of Forssman shock. In vitro uptake of C3b and C4b complement fragments onto corpusculate immune complexes was significantly inhibited by IVIG. Studies that involved patients suffering from disorders with pathogenesis similar to animal models of complement-mediated immune injury fully supported the hypothesis that IVIG interacts with activated complement components and prevents their deposition on target cells. The author's results suggest that IVIG can be an effective modulator of inappropriate complement attack.
Assuntos
Adjuvantes Imunológicos/farmacologia , Doenças Autoimunes/terapia , Proteínas do Sistema Complemento/efeitos adversos , Imunoglobulinas Intravenosas/farmacologia , Anemia Hemolítica Autoimune/imunologia , Anemia Hemolítica Autoimune/terapia , Animais , Doenças Autoimunes/etiologia , Dermatomiosite/imunologia , Dermatomiosite/terapia , Eritrócitos/imunologia , Antígeno de Forssman , Cobaias , Hemoglobinúria Paroxística/imunologia , Hemoglobinúria Paroxística/terapia , Humanos , Imunoglobulinas Intravenosas/administração & dosagemRESUMO
El granuloma facial es una entidad clínica e histológica bien definida, cuya etiología permanece desconocida. Los hallazgos por inmunofluorescencia directa de depósitos de inmunoglobulinas y complemento en las lesiones, inician un nuevo camino de investigación que aún no ha sido bien aclarado, ya que se alternan estudios positivos con otros megativos. Estudiamos 4 pacientes, 3 hombres y una mujer, con un rango de edad de 33 a 55 años; el tiempo de evolución de la enfermedad osciló entre 1 y 14 años. Todos los pacientes tenían compromiso facial. Uno presentó lesiones múltiples y otro se acompañaba de lesiones extrafaciales. La inmunofluorescencia directa fue positiva en dos casos, hallando depósitos granulares de IgA en zona de membrana basal. La IgG, IgM, IgE y complemento fueron negativos en los 4 casos. Las distintas características de las inmunoglobulinas más un factor ambiental (rayos ultravioletas) u otro, llevaría a la IgA de la circulación a los tejidos. Posteriormente lo haría la IgG en la respuesta secundaria
Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Face/patologia , Granuloma/imunologia , Cadeias alfa de Imunoglobulina/efeitos adversos , Cadeias gama de Imunoglobulina/efeitos adversos , Reação de Arthus/diagnóstico , Reação de Arthus/imunologia , Proteínas do Sistema Complemento/efeitos adversos , Proteínas do Sistema Complemento/análise , Proteínas do Sistema Complemento/imunologia , Granuloma/diagnóstico , Granuloma/patologia , Imunoglobulina A , Imunoglobulina A/análise , Imunoglobulina G , Imunoglobulina G/análise , Imunoglobulina M , Imunoglobulina M/análise , Imunofluorescência/estatística & dados numéricos , Imunofluorescência/normas , Vasculite/diagnóstico , Vasculite/imunologia , Vasculite/fisiopatologiaRESUMO
El granuloma facial es una entidad clínica e histológica bien definida, cuya etiología permanece desconocida. Los hallazgos por inmunofluorescencia directa de depósitos de inmunoglobulinas y complemento en las lesiones, inician un nuevo camino de investigación que aún no ha sido bien aclarado, ya que se alternan estudios positivos con otros megativos. Estudiamos 4 pacientes, 3 hombres y una mujer, con un rango de edad de 33 a 55 años; el tiempo de evolución de la enfermedad osciló entre 1 y 14 años. Todos los pacientes tenían compromiso facial. Uno presentó lesiones múltiples y otro se acompañaba de lesiones extrafaciales. La inmunofluorescencia directa fue positiva en dos casos, hallando depósitos granulares de IgA en zona de membrana basal. La IgG, IgM, IgE y complemento fueron negativos en los 4 casos. Las distintas características de las inmunoglobulinas más un factor ambiental (rayos ultravioletas) u otro, llevaría a la IgA de la circulación a los tejidos. Posteriormente lo haría la IgG en la respuesta secundaria(AU)
Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Granuloma/imunologia , Face/patologia , Cadeias alfa de Imunoglobulina/efeitos adversos , Cadeias gama de Imunoglobulina/efeitos adversos , Granuloma/diagnóstico , Granuloma/patologia , Imunofluorescência/estatística & dados numéricos , Imunofluorescência/normas , Reação de Arthus/diagnóstico , Reação de Arthus/imunologia , Vasculite/diagnóstico , Vasculite/fisiopatologia , Vasculite/imunologia , Imunoglobulina A/análise , Imunoglobulina A/diagnóstico , Imunoglobulina G/análise , Imunoglobulina G/diagnóstico , Imunoglobulina M/análise , Imunoglobulina M/diagnóstico , Proteínas do Sistema Complemento/análise , Proteínas do Sistema Complemento/efeitos adversos , Proteínas do Sistema Complemento/imunologiaAssuntos
Hemólise , Reação Transfusional , Espasmo Brônquico/etiologia , Proteínas do Sistema Complemento/efeitos adversos , Citocinas/efeitos adversos , Febre/etiologia , Antígenos HLA/imunologia , Humanos , Hipersensibilidade/etiologia , Hipotensão/etiologia , Imunização , Infecções/transmissão , Taquicardia/etiologiaRESUMO
Complement-mediated nucleated cell death has been shown to be independent of colloid-osmotic swelling. In contrast, other factors (e.g. Ca2+ influx) are of importance in the induction of cell death. In this communication, the sequential morphological features of complement-mediated cell injury have been studied by electron microscopy and compared with biochemical data (ATP content and LDH release). It was observed that immediately after C5b-8 lesion formation, although the overall cell, morphology is well preserved, the mitochondria display an "ultracondensed" appearance. Upon addition of C9, the mitochondria remain initially condensed, but swell progressively with final formation of flocculent densities. The nuclei become progressively edematous, with concurrent disappearance of heterochromatin. The nucleoli lose their associated chromatin and display segregation of their components with formation of markedly electron-dense filamentous deposits. The nuclear envelope remains initially intact, but subsequently progressive dilatation of the associated perinuclear RER cisterna and distention of the nuclear pores associated with leakage of chromatin into the cytoplasm are seen. The larger cell organelles (including mitochondria, ER, Golgi apparatus, etc.) become clustered around the nucleus, concurrently with marked edema of the outer cytoplasm and bleb formation. The RER cisternae become dilated, whereas the Golgi complex disappears. Relatively early on the plasma membrane shows breaks in continuity. The pattern of these changes--potentially related to Ca2+ influx, ATP efflux and overall metabolic depletion--corresponds to the previously described model of cell reaction to injury, confirming the dynamic nature of the process. The morphology of cell death in this model shares some features, e.g., the nucleolar changes, with "apoptosis" (programmed cell death). However, the overall pattern appears to correspond more to "necrosis," characterized by loss of volume control and mitochondrial abnormalities.
Assuntos
Células/ultraestrutura , Proteínas do Sistema Complemento/efeitos adversos , Trifosfato de Adenosina/metabolismo , Animais , Carcinoma de Ehrlich , Morte Celular , Células/metabolismo , Humanos , L-Lactato Desidrogenase/metabolismo , Camundongos , Microscopia Eletrônica , Modelos Biológicos , Células Tumorais CultivadasAssuntos
Antígenos CD59 , Proteínas de Transporte , Proteínas do Sistema Complemento/efeitos adversos , Eritrócitos/fisiologia , Transporte Biológico , Proteínas Sanguíneas/fisiologia , Antígenos CD55 , Ativação do Complemento , Proteínas Inativadoras do Complemento/fisiologia , Proteínas do Sistema Complemento/fisiologia , Membrana Eritrocítica/metabolismo , Glucose/farmacocinética , Humanos , Proteínas de Membrana/fisiologia , Permeabilidade , Sódio/farmacocinéticaRESUMO
Rat kidneys (donor organs) were perfused in an in-vitro perfusion circuit using blood or modified blood from the dog (recipient). Hyperacute xenogeneic rejection (HXR) in widely divergent species system could even be seen, when preformed natural antibodies were absent. These data presented suggest that this form of HXR is at least partially induced by nonspecific (equals nonimmunologic complement activation, followed by complement mediated disease (liberation of vasoactive and other substances leading to increased permeability. e. g. Anaphylatoxin) of the donor kidneys.